Background/Aims: Enamel-renal syndrome is characterized by nephrocalcinosis, enamel defects, gingival hyperplasia and eruption failures. It has been recently identified that recessive mutations in the FAM20A gene result in amelogenesis imperfecta (AI)-gingival fibromatosis. The aim of this research to determine whether AI patients with known -FAM20A mutations also have nephrocalcinosis. Methods: Complete oral and radiological examinations were performed for all participating family members. Renal examinations were performed using ultrasound. Results: The teeth were evaluated for severe loss, and multiple eruption failures were evident from the clinical and radiological examinations. Unexpected extensive and fast crown resorption was found by radiological examination. Renal ultrasound revealed bilateral nephrocalcinosis in both affected individuals. Recessive FAM20A mutations can cause nephrocalcinosis in addition to the oral phenotype. Conclusion: AI patients with similar clinical phenotypes and FAM20A mutations should be examined for nephropathy even if they lack pertinent symptoms. Nephrology referral is warranted for patients who have clinical phenotypes related to AI-gingival fibromatosis even if they are not symptomatic.

Keywords:
Amelogenesis imperfecta, Enamel, FAM20A, Nephrocalcinosis
1.
Witkop CJ Jr: Amelogenesis imperfecta, dentinogenesis imperfecta and dentin dysplasia revisited: problems in classification. J Oral Pathol 1988; 17: 547–553.
2.
Lagerström M, Dahl N, Nakahori Y, Nakagome Y, Bäckman B, Landegren U, Pettersson U: A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1). Genomics 1991; 10: 971–975.
3.
Kim JW, Simmer JP, Hu YY, Lin BP, Boyd C, Wright JT, Yamada CJ, Rayes SK, Feigal RJ, Hu JC: Amelogenin p.M1T and p.W4S mutations underlying hypoplastic X-linked amelogenesis imperfecta. J Dent Res 2004; 83: 378–383.
4.
Rajpar MH, Harley K, Laing C, Davies RM, Dixon MJ: Mutation of the gene encoding the enamel-specific protein, enamelin, causes autosomal-dominant amelogenesis imperfecta. Hum Mol Genet 2001; 10: 1673–1677.
5.
Kang HY, Seymen F, Lee SK, Yildirim M, Tuna EB, Patir A, Lee KE, Kim JW: Candidate gene strategy reveals ENAM mutations. J Dent Res 2009; 88: 266–269.
6.
Poulter JA, Murillo G, Brookes SJ, Smith CE, Parry DA, Silva S, Kirkham J, Inglehearn CF, Mighell AJ: Deletion of ameloblastin exon 6 is associated with amelogenesis imperfecta. Hum Mol Genet 2014; 23: 5317–5324.
7.
Kim JW, Simmer JP, Hart TC, Hart PS, Ramaswami MD, Bartlett JD, Hu JC: MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J Med Genet 2005; 42: 271–275.
8.
Gasse B, Karayigit E, Mathieu E, Jung S, Garret A, Huckert M, Morkmued S, Schneider C, Vidal L, Hemmerlé J, Sire JY, Bloch-Zupan A: Homozygous and compound heterozygous MMP20 mutations in amelogenesis imperfecta. J Dent Res 2013; 92: 598–603.
9.
Hart PS, Hart TC, Michalec MD, Ryu OH, Simmons D, Hong S, Wright JT: Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J Med Genet 2004; 41: 545–549.
10.
Kim JW, Lee SK, Lee ZH, Park JC, Lee KE, Lee MH, Park JT, Seo BM, Hu JC, Simmer JP: FAM83H mutations in families with autosomal-dominant hypocalcified amelogenesis imperfecta. Am J Hum Genet 2008; 82: 489–494.
11.
Parry DA, Brookes SJ, Logan CV, Poulter JA, El-Sayed W, Al-Bahlani S, Al Harasi S, Sayed J, Raïf el M, Shore RC, Dashash M, Barron M, Morgan JE, Carr IM, Taylor GR, Johnson CA, Aldred MJ, Dixon MJ, Wright JT, Kirkham J, Inglehearn CF, Mighell AJ: Mutations in C4orf26, encoding a peptide with in vitro hydroxyapatite crystal nucleation and growth activity, cause amelogenesis imperfecta. Am J Hum Genet 2012; 91: 565–571.
12.
El-Sayed W, Parry DA, Shore RC, Ahmed M, Jafri H, Rashid Y, Al-Bahlani S, Al Harasi S, Kirkham J, Inglehearn CF, Mighell AJ: Mutations in the beta propeller WDR72 cause autosomal-recessive hypomaturation amelogenesis imperfecta. Am J Hum Genet 2009; 85: 699–705.
13.
Lee SK, Seymen F, Lee KE, Kang HY, Yildirim M, Tuna EB, Gencay K, Hwang YH, Nam KH, De La Garza RJ, Hu JC, Simmer JP, Kim JW: Novel WDR72 mutation and cytoplasmic localization. J Dent Res 2010; 89: 1378–1382.
14.
Parry DA, Poulter JA, Logan CV, Brookes SJ, Jafri H, Ferguson CH, Anwari BM, Rashid Y, Zhao H, Johnson CA, Inglehearn CF, Mighell AJ: Identification of mutations in SLC24A4, encoding a potassium-dependent sodium/calcium exchanger, as a cause of amelogenesis imperfecta. Am J Hum Genet 2013; 92: 307–312.
15.
Seymen F, Lee KE, Le CG, Yildirim M, Gencay K, Lee ZH, Kim JW: Exonal deletion of SLC24A4 causes hypomaturation amelogenesis imperfecta. J Dent Res 2014; 93: 366–370.
16.
O’Sullivan J, Bitu CC, Daly SB, Urquhart JE, Barron MJ, Bhaskar SS, Martelli-Júnior H, dos Santos Neto PE, Mansilla MA, Murray JC, Coletta RD, Black GC, Dixon MJ: Whole-exome sequencing identifies FAM20A mutations as a cause of amelogenesis imperfecta and gingival hyperplasia syndrome. Am J Hum Genet 2011; 88: 616–620.
17.
Cho SH, Seymen F, Lee KE, Lee SK, Kweon YS, Kim KJ, Jung SE, Song SJ, Yildirim M, Bayram M, Tuna EB, Gencay K, Kim JW: Novel FAM20A mutations in hypoplastic amelogenesis imperfecta. Hum Mutat 2012; 33: 91–94.
18.
Volodarsky M, Zilberman U, Birk OS: Novel FAM20A mutation causes autosomal recessive amelogenesis imperfecta. Arch Oral Biol 2015; 60: 919–922.
19.
Wang SK, Reid BM, Dugan SL, Roggenbuck JA, Read L, Aref P, Taheri AP, Yeganeh MZ, Simmer JP, Hu JC: FAM20A mutations associated with enamel renal syndrome. J Dent Res 2014; 93: 42–48.
20.
Jaureguiberry G, De la Dure-Molla M, Parry D, Quentric M, Himmerkus N, Koike T, Poulter J, Klootwijk E, Robinette SL, Howie AJ, Patel V, Figueres ML, Stanescu HC, Issler N, Nicholson JK, Bockenhauer D, Laing C, Walsh SB, McCredie DA, Povey S, Asselin A, Picard A, Coulomb A, Medlar AJ, Bailleul-Forestier I, Verloes A, Le Caignec C, Roussey G, Guiol J, Isidor B, Logan C, Shore R, Johnson C, Inglehearn C, Al-Bahlani S, Schmittbuhl M, Clauss F, Huckert M, Laugel V, Ginglinger E, Pajarola S, Spartà G, Bartholdi D, Rauch A, Addor MC, Yamaguti PM, Safatle HP, Acevedo AC, Martelli-Júnior H, dos Santos Netos PE, Coletta RD, Gruessel S, Sandmann C, Ruehmann D, Langman CB, Scheinman SJ, Ozdemir-Ozenen D, Hart TC, Hart PS, Neugebauer U, Schlatter E, Houillier P, Gahl WA, Vikkula M, Bloch-Zupan A, Bleich M, Kitagawa H, Unwin RJ, Mighell A, Berdal A, Kleta R: Nephrocalcinosis (enamel renal syndrome) caused by autosomal recessive FAM20A mutations. Nephron Physiol 2012; 122: 1–6.
21.
Kantaputra PN, Kaewgahya M, Khemaleelakul U, Dejkhamron P, Sutthimethakorn S, Thongboonkerd V, Iamaroon A: Enamel-renal-gingival syndrome and FAM20A mutations. Am J Med Genet A 2014; 164: 1–9.
22.
de la Dure-Molla M, Quentric M, Yamaguti PM, Acevedo AC, Mighell AJ, Vikkula M, Huckert M, Berdal A, Bloch-Zupan A: Pathognomonic oral profile of enamel renal syndrome (ERS) caused by recessive FAM20A mutations. Orphanet J Rare Dis 2014; 9: 84.
23.
Cho SH, Seymen F, Lee KE, Lee SK, Kweon YS, Kim KJ, Jung SE, Song SJ, Yildirim M, Bayram M, Tuna EB, Gencay K, Kim JW: Novel FAM20A mutations in hypoplastic amelogenesis imperfecta. Hum Mutat 2012; 33: 91–94.
24.
Nalbant D, Youn H, Nalbant SI, Sharma S, Cobos E, Beale EG, Du Y, Williams SC: FAM20: an evolutionarily conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics 2005; 6: 11.
25.
Tagliabracci VS, Engel JL, Wen J, Wiley SE, Worby CA, Kinch LN, Xiao J, Grishin NV, Dixon JE: Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science 2012; 336: 1150–1153.
26.
Eames BF, Yan YL, Swartz ME, Levic DS, Knapik EW, Postlethwait JH, Kimmel CB: Mutations in fam20b and xylt1 reveal that cartilage matrix controls timing of endochondral ossification by inhibiting chondrocyte maturation. PLoS Genet 2011; 7:e1002246.
27.
Oliveira B, Kleta R, Bockenhauer D, Walsh SB: Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. Am J Physiol Renal Physiol 2016; 311:F1243–F1252.
28.
Ammenti A, Pelizzoni A, Cecconi M, Molinari PP, Montini G: Nephrocalcinosis in children: a retrospective multi-centre study. Acta Paediatr 2009; 98: 1628–1631.
29.
Lubinsky M, Angle C, Marsh PW, Witkop CJ Jr: Syndrome of amelogenesis imperfecta, nephrocalcinosis, impaired renal concentration, and possible abnormality of calcium metabolism. Am J Med Genet 1985; 20: 233–243.
30.
Hall RK, Phakey P, Palamara J, McCredie DA: Amelogenesis imperfecta and nephrocalcinosis syndrome. Case studies of clinical features and ultrastructure of tooth enamel in two siblings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 583–592.
31.
Dellow EL, Harley KE, Unwin RJ, Wrong O, Winter GB, Parkins BJ: Amelogenesis imperfecta, nephrocalcinosis, and hypocalciuria syndrome in two siblings from a large family with consanguineous parents. Nephrol Dial Transplant 1998; 13: 3193–3196.
32.
Normand de la Tranchade I, Bonarek H, Marteau JM, Boileau MJ, Nancy J: Amelogenesis imperfecta and nephrocalcinosis: a new case of this rare syndrome. J Clin Pediatr Dent 2004; 27: 171–175.
33.
Paula LM, Melo NS, Silva Guerra EN, Mestrinho DH, Acevedo AC: Case report of a rare syndrome associating amelogenesis imperfecta and nephrocalcinosis in a consanguineous family. Arch Oral Biol 2005; 50: 237–242.
34.
Fu XJ, Nozu K, Goji K, Ikeda K, Kamioka I, Fujita T, Kaito H, Nishio H, Iijima K, Matsuo M: Enamel-renal syndrome associated with hypokalaemic metabolic alkalosis and impaired renal concentration: a novel syndrome? Nephrol Dial Transplant 2006; 21: 2959–2962.
35.
Elizabeth J, Lakshmi Priya E, Umadevi KM, Ranganathan K: Amelogenesis imperfecta with renal disease – a report of two cases. J Oral Pathol Med 2007; 36: 625–628.
36.
Martelli-Júnior H, dos Santos Neto PE, de Aquino SN, de Oliveira Santos CC, Borges SP, Oliveira EA, Lopes MA, Coletta RD: Amelogenesis imperfecta and nephrocalcinosis syndrome: a case report and review of the literature. Nephron Physiol 2011; 118:p62–p65.
37.
Kala Vani SV, Varsha M, Sankar YU: Enamel renal syndrome: a rare case report. J Indian Soc Pedod Prev Dent 2012; 30: 169–172.
38.
Ashkenazi M, Rafe Z, Sarnat H, Levin L: Nephrocalcinosis associated with continuous enamel hypoplasia and severe alveolar bone loss: a case report and literature review. Pediatr Dent 2014; 36: 250–253.
39.
Bhesania D, Arora A, Kapoor S: Enamel renal syndrome with associated amelogenesis imperfecta, nephrolithiasis, and hypocitraturia: a case report. Imaging Sci Dent 2015; 45: 181–185.
40.
Poulter JA, Smith CE, Murrillo G, Silva S, Feather S, Howell M, Crinnion L, Bonthron DT, Carr IM, Watson CM, Inglehearn CF, Mighell AJ: A distinctive oral phenotype points to FAM20A mutations not identified by Sanger sequencing. Mol Genet Genomic Med 2015; 3: 543–549.
41.
Vogel P, Hansen GM, Read RW, Vance RB, Thiel M, Liu J, Wronski TJ, Smith DD, Jeter-Jones S, Brommage R: Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c null mice. Vet Pathol 2012; 49: 998–1017.
42.
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL: New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629–637.
43.
Selistre L, De Souza V, Cochat P, Antonello IC, Hadj-Aissa A, Ranchin B, Dolomanova O, Varennes A, Beyerle F, Bacchetta J, Dubourg L: GFR estimation in adolescents and young adults. J Am Soc Nephrol 2012; 23: 989–996.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.